An interventional study of TOMO in Renal Insufficiency, Chronic and Peer Group, sponsored by University Hospital, Caen. Not yet recruiting at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by University Hospital, Caen · Not applicable, Interventional, and Supportive care
Among 238 studies in Renal Insufficiency, Chronic with a site in France — 56 open to participants now, 70 under way, 17 of them phase 3. Renal Insufficiency, Chronic · France.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, this one is the 67th largest by planned enrollment of the 165 interventional ones that give a count, is one of 2 that started in 2027, is one of 63 with no phase, reaches primary completion later than 53 of the 69 other live ones, and was the 238th registered.
3,090 studies on the registry are indexed under Renal Insufficiency, Chronic; 698 are open to participants now.
Browse Renal Insufficiency, Chronic studies →56 of the 238 studies in Renal Insufficiency, Chronic with a site in France are open now. Recruiting first, the newest first:
Institut National de la Santé Et de la Recherche Médicale, France · Sites in France
Ages 18+ · Healthy volunteers
AstraZeneca · Sites in France, United States, Argentina and 24 more countries
Ages 18–99
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18–80
AstraZeneca · Sites in France, United States, Argentina and 34 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, China and 5 more countries
Ages 2–18
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 111 (26%) stop at 75 or younger; 45 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
238 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 31 · Phase 3 62 · Phase 4 9
First in 2003; this study’s year is marked. 2 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 73 across 2,157 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 170 across the 165 interventional studies, 165 across the 73 observational. Of the 145 that completed or were terminated, 50 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
94 of 238 have an industry lead sponsor. The 10 most frequent:
University Hospital, Caen is the lead sponsor of 513 studies on the registry; 83 are open to participants now.
University Hospital, Caen has 7 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
21 of the studies in Renal Insufficiency, Chronic with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07107945Phase 3Boehringer IngelheimA Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids) | 2027-04-16 |
| NCT03969329Phase 3AmgenA Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis | 2027-06-30 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT06692231Centre Hospitalier de VichyImpact of Hospital Pharmacist Intervention on Medication Management in Dialysis Patients | 2026-11-30 |
Add all 21 to your calendar (.ics) → With an account.
Among the 238 studies in Renal Insufficiency, Chronic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Background: Patients living with chronic kidney disease (CKD) face numerous therapeutic decisions throughout their care pathway, particularly regarding the choice of kidney replacement therapy modality. In this context, shared decision-making plays a central role in enabling patients to actively participate in treatment decisions according to their preferences and quality-of-life expectations. However, several studies have shown that the information provided to patients may sometimes be insufficient and that patients' preferences are not always aligned with the treatment modalities ultimately initiated.
Patients with CKD may also feel overwhelmed by their diagnosis and by the large amount of medical information they receive. Emotional responses to the disease vary considerably and are associated with heterogeneous needs for information and support, which may contribute to impaired quality of life.
In this context, peer support, based on the sharing of experiences between individuals facing similar situations, may represent a valuable complement to the support provided by healthcare teams.
Methods: A pragmatic, comparative, open-label, randomised, parallel-group, multicentre trial will be conducted involving 260 patients at six nephrology centres in French region. The primary objective is to compare, over a 12-month follow-up period, quality-adjusted life years (QALYs) - which take into account both survival time and health-related quality of life - in patients with stage IV chronic kidney disease, between a group of patients receiving standard care and support from the nephrology team and a group using the TOMO platform in addition to standard care Discussion: At a time when digital technology in healthcare is establishing itself as a means of ensuring access, personalised care and continuity of care, Tomo® offers a structured, secure and supervised peer-support model. We hypothesise that offering peer support, in addition to the standard care provided fro the nephrology team to patients with stage IV chronic kidney disease, should improve their life expectancy and well-being.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with stage 4 chronic kidney disease who do not use the TOMO platform or any other digital solution that facilitates connections with peer mentors. Usual care and support provided by the healthcare team remain unchanged. Care organization may vary across participating centers
Patients with stage 4 chronic kidney disease who use the TOMO platform, which connects them with a peer mentor living with the same condition. Usual care and support provided by the nephrology team remain unchanged
Behavioral: TOMO
A digital peer-support intervention connecting patients with stage 4 chronic kidney disease to peer mentors living with the same condition, in addition to usual nephrology care
QALYs
Difference in cumulative quality-adjusted life years (QALYs) between the control and intervention groups. QALYs will be calculated from utility scores derived from the EQ-5D-5L questionnaire using the area under the curve (AUC) method.
Time frame: Baseline (M0), 3 months (M3), 6 months (M6), and 12 months (M12) after randomization.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Feb 2029, 24 months later.
Of 576 non-industry interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 45. This study's planned 24 months is close to that.
Counting every sponsor, half of 616 studies reached it within 23 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Renal Insufficiency, Chronic →